Clinicopathological characteristics of the immunotherapy data set
| Characteristics | All (n=123) | Overall survival | Progression-free survival | ||||
| High-risk group (n=79) | Low-risk group (n=44) | P value | High-risk group (n=91) | Low-risk group (n=32) | P value | ||
| Age, year | 61.8±10.2 | 61.5±10.9 | 62.4±8.7 | 0.646 | 62.5±10.7 | 60.0±8.2 | 0.247 |
| Sex | 0.424 | 0.512 | |||||
| Male | 101 (82.1) | 67 (84.8) | 34 (77.3) | 73 (80.2) | 28 (87.5) | ||
| Female | 22 (17.9) | 12 (15.2) | 10 (22.7) | 18 (19.8) | 4 (12.5) | ||
| Smoking status | 0.685 | 0.533 | |||||
| Current or former smoker | 77 (62.6) | 51 (64.6) | 26 (51.9) | 55 (60.4) | 22 (68.8) | ||
| Never smoked | 46 (37.4) | 27 (40.9) | 18 (40.9) | 36 (39.6) | 10 (31.2) | ||
| ECOG performance-status score | 0.364 | 0.993 | |||||
| 0 | 11 (8.9) | 7 (8.9) | 4 (9.1) | 8 (8.8) | 3 (9.4) | ||
| 1 | 104 (84.6) | 65 (82.3) | 39 (88.6) | 77 (84.6) | 27 (84.4) | ||
| 2 | 8 (6.5) | 7 (8.9) | 1 (2.3) | 6 (6.6) | 2 (6.2) | ||
| Tumor histologic type | 0.728 | 0.247 | |||||
| Adenocarcinoma | 80 (65.0) | 50 (63.3) | 30 (68.2) | 56 (61.5) | 24 (75.0) | ||
| Squamous cell carcinoma | 43 (35.0) | 29 (36.7) | 14 (31.8) | 35 (38.5) | 8 (25.0) | ||
| Pathological stage | 0.974 | 0.492 | |||||
| III | 18 (14.6) | 11 (13.9) | 7 (15.9) | 15 (16.5) | 3 (9.4) | ||
| IV | 105 (85.4) | 68 (86.1) | 37 (84.1) | 76 (83.5) | 29 (90.6) | ||
| EGFR mutation | 0.618 | 0.983 | |||||
| No mutation | 94 (76.4) | 62 (78.5) | 32 (72.7) | 69 (75.8) | 25 (78.1) | ||
| Mutation | 29 (23.6) | 17 (21.5) | 12 (27.3) | 22 (24.2) | 7 (21.9) | ||
| TMBRB | <0.001 | <0.001 | |||||
| Mean | 0.55±0.16 | 0.46±0.13 | 0.71±0.05 | 0.62±0.10 | 0.34±0.11 | ||
| Range | 0.07 to 0.83 | 0.07 to 0.61 | 0.61 to 0.83 | 0.46 to 0.83 | 0.07 to 0.46 | ||
Categorical data are shown as numbers (%) and continuous data as mean±SD.
ECOG, Eastern Cooperative Oncology Group; EGFR, Epidermal Growth Factor Receptor; TMBRB, tumor mutational burden radiomic biomarker.